{"filing":{"accession_number":"0001213900-26-070193","cik":"0001388320","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"ea0295259-8k_actinium.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026070193/ea0295259-8k_actinium.htm"},"events":[{"id":11965,"run_id":10528,"accession_number":"0001213900-26-070193","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"The Company received a notice from NYSE American on May 27, 2026, indicating non-compliance with continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide due to insufficient stockholders' equity ($4.0 million minimum required) combined with losses in three of four recent fiscal years. The June 18, 2026 submission of a compliance plan is a direct response to delisting risk and represents a material disclosure of failure to satisfy a continued listing rule.","company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8689,"accession_number":"0001213900-26-070193","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The Company received a notice from NYSE American on May 27, 2026, indicating non-compliance with continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide due to insufficient stockholders' equity ($4.0 million minimum required) combined with losses in three of four recent fiscal years. The June 18, 2026 submission of a compliance plan is a direct response to delisting risk and represents a material disclosure of failure to satisfy a continued listing rule.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:03:11.524922+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8689,"accession_number":"0001213900-26-070193","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The Company received a notice from NYSE American on May 27, 2026, indicating non-compliance with continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide due to insufficient stockholders' equity ($4.0 million minimum required) combined with losses in three of four recent fiscal years. The June 18, 2026 submission of a compliance plan is a direct response to delisting risk and represents a material disclosure of failure to satisfy a continued listing rule.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T21:03:11.524922+00:00","company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","filing_date":"2026-06-18"}]}